

29 August 2025

## 2025 ANNUAL GENERAL MEETING – KEY DATES

In accordance with ASX Listing Rule 3.13.1, Botanix Pharmaceuticals Ltd (ASX:BOT) (“**Botanix**” or the “**Company**”) is pleased to announce the 2025 Annual General Meeting (“**AGM**”) has been scheduled for 9.30am (WST) on Thursday, 20 November 2025 at the offices of BDO, Level 9, Mia Yellagonga Tower 2, 5 Spring Street, Perth, Western Australia.

An item of business at the AGM will be the re-election of directors. The closing date for the receipt of director nominations is Thursday, 2 October 2025 being 35 business days before the date of the AGM. Nominations must be received at the Company’s registered office no later than 5.00pm (WST) on Thursday, 2 October 2025.

Further information on the AGM will be provided in the Notice of AGM which will be released to ASX on or before Friday, 17 October 2025.

This ASX announcement is authorised for release by the Board.

### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX: BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for its lead product *Sofdra*<sup>™</sup> for the treatment of primary axillary hyperhidrosis. *Sofdra*<sup>™</sup> is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: <http://www.botanixpharma.com/>

### For more information, please contact:

#### General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

#### Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

#### Media enquiries

Haley Chartres

H<sup>^</sup>CK

P: +61 423 139 163

[haley@hck.digital](mailto:haley@hck.digital)